Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases.
Palliative radiotherapy is effective in the treatment of bone metastases but is under-utilized, possibly because it is perceived to be expensive. We performed a cost-utility analysis of palliative radiotherapy for bone metastases, evaluating both the actual cost of radiotherapy as well as its impact on quality of life by adjusting for the variation in response to treatment. Hospital records between July 1991 and July 1996 were reviewed to ascertain the number of patients treated with palliative radiotherapy for bone metastases, the average number of fields of radiation delivered to each patient and the average duration of survival. Partial and complete response rates to palliative radiotherapy were obtained from a review of all published randomized controlled trials of radiation treatment of bone metastases. Utility values were assigned to the response rates, and an overall adjusted response rate to radiotherapy was derived. The cost of delivering a field of radiation was calculated. The total cost was divided by the total number of response months to give a utility-adjusted cost per month of palliative radiotherapy. The utility-adjusted cost per month of palliative radiotherapy of bone metastases was found to be AUS dollars 100 per month or AUS dollars 1200 per utility-adjusted life-year. This study demonstrates that, contrary to popular perception, palliative radiotherapy is a cost-effective treatment modality for bone metastases.
Barton
Michael B
MB
Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Health Service, New South Wales, Australia. Michael.Barton@swahs.nsw.gov.au
Jacob
Susannah A
SA
Gebsky
Val
V
D001315:Australia; D001859:Bone Neoplasms / Q000191:economics / Q000532:radiotherapy* / Q000556:secondary*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006801:Humans; D010166:Palliative Care / Q000191:economics* / Q000706:statistics & numerical data